JETREA® Selected for Single Technology Appraisal (STA) by the UK's National Institute for Health and Clinical Excellence (NICE)

JETREA® Selected for Single Technology Appraisal (STA) by the UK's National Institute for Health and Clinical Excellence (NICE) PR Newswire LEUVEN, Belgium, November 27, 2012 LEUVEN, Belgium, November 27, 2012 /PRNewswire/ -- ThromboGenics NV (Euronext Brussels: THR), an integrated biopharmaceutical company focused on developing and ®commercializing innovative ophthalmic medicines, today announces that JETREA (ocriplasmin) has been selected to receive a Single Technology Appraisal (STA) from the UK's National Institute for Health and Clinical Excellence (NICE). ®The outcome of the STA, in the form of NICE guidance, is expected later in 2013, following the launch of JETREA in the UK. ®The JETREA European Marketing Authorisation Application is currently under review by the European Medicines ®Agency. A decision on European approval is expected in the first half of 2013. JETREA was recently approved by the U.S. Food and Drugs Administration for the treatment of symptomatic Vitreomacular Adhesion (VMA). In March 2012, ThromboGenics signed a strategic partnership with Alcon (Novartis) for the commercialization of ocriplasmin outside the United States The NICE STA process is designed to provide recommendations on the use of new medicines in the National Health Service (NHS). The STA is specifically designed to appraise a single product with a single indication, and enables NICE to produce guidance soon after the technology is introduced in the UK.